Teva Pharmaceutical Industries Ltd (TEVA) shares surged 8.62% in pre-market trading on Wednesday following the release of its better-than-expected first-quarter 2025 earnings report. The world's largest generic drugmaker demonstrated resilience in a challenging market, with strong performance from its branded drug portfolio.

Teva reported adjusted earnings of $0.52 per share for the quarter ended March 31, surpassing the mean analyst estimate of $0.46 per share. This represents a significant improvement from the $0.48 per share reported in the same quarter last year. Revenue rose 1.9% to $3.89 billion, slightly below the anticipated $3.99 billion, but still showing growth in a competitive market environment.

The company's impressive results were driven by strong sales gains in a trio of its branded drugs targeting migraines, Huntington's disease, and schizophrenia. This performance underscores Teva's successful efforts to diversify its product portfolio beyond generic medications. Additionally, Teva has updated its full-year 2025 guidance, raising its non-GAAP diluted EPS forecast to a range of $2.45 to $2.65, up from the previous guidance of $2.35 to $2.65. The company now expects full-year 2025 revenue to range from $16.8 billion to $17.2 billion.

Investors are reacting positively to Teva's ability to navigate challenges in the pharmaceutical industry, including potential impacts from U.S. tariffs, which the company stated would have an immaterial financial impact. The pre-market stock surge reflects growing confidence in Teva's strategic direction and its potential for sustained growth in the coming years.